Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparative, randomised, two period, multi-centre, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI (Novartis) in cystic fibrosis patients with bronchopulmonary chronic Pseudomonas aeruginosa (PA) infection

Next Previous
X
Search
Trial Profile

A comparative, randomised, two period, multi-centre, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI (Novartis) in cystic fibrosis patients with bronchopulmonary chronic Pseudomonas aeruginosa (PA) infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus First in man; Pharmacokinetics
  • Acronyms T100
  • Sponsors PARI Pharma GmbH

    • Most Recent Events

    • 09 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 31 Aug 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 14 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top